Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction

Korean Journal of Internal Medicine

Volumn 21, Issue 4, 2006, Pages 252-255

  Hwang, Seung Jae ^a   Park, Jong Won ^a   Lee, Sehe Dong ^a   Kim, Gyong Jung ^a   Sin, Cheol Ho ^a   Nam, Seung Hyun ^a   Kim, Bong Seog ^a  

^a Seoul Veterans Hospital   (South Korea)

Author keywords

Capecitabine; Gastric cancer; Liver failure; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; OXALIPLATIN; PLATINUM COMPLEX; PRODRUG;

ADENOCARCINOMA; ARTICLE; CASE REPORT; DRUG COMBINATION; FOLLOW UP; GASTRECTOMY; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PRODRUGS; STOMACH NEOPLASMS;

EID: 33846984287     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2006.21.4.252     Document Type: Article

References (8)

1. Central Cancer Registry Center in Korea. Annual report of the central cancer registry in Korea (2000.1-2001.12). Ministry of Health and Welfare, Republic of Korea, 2002
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advancer gastric cancer. Ann Oncol 8:163-168, 1997
4. Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B. Effect of hepatic dysfunction due to liver metastates on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5:1696-1702, 1999
5. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Renz HJ, Graham M, Longmate J, Takimoto CH, Ivy P. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 30:14-19, 2003
6. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995
7. Schull B, Scheithauer W, Kornek GV. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie 26:578-580, 2003
8. Park YH, Kim BS, Ryoo BY, Yang SH. Oxaliplatin and capecitabine combination chemotherapy for patients with advnaced gastric cancer: a pilot study results. J Clin Oncol 23:235a, 2005